The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study.
 
Patrick M. Forde
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Janssen
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals; Kyowa Hakko Kirin (Inst); Novartis (Inst)
 
Zhuoxin Sun
No Relationships to Disclose
 
Valsamo Anagnostou
Research Funding - Bristol-Myers Squibb
 
Hedy L. Kindler
Honoraria - AstraZeneca
Consulting or Advisory Role - Aldeyra Therapeutics; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Deciphera; ERYTECH Pharma; Five Prime Therapeutics; Inventiva Pharma; Inventiva Pharma; ipsen; Kyowa Hakko Kirin; Merck; Paradox Therapeutics
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Polaris (Inst); Polaris (Inst); Roche/Genentech (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
William T. Purcell
No Relationships to Disclose
 
Bernardo H. L. Goulart
No Relationships to Disclose
 
Arkadiusz Z. Dudek
Leadership - IGF Oncology; Martell diagnostic; Squarex Pharma; TTC Oncology; Vanquish Oncology
Stock and Other Ownership Interests - Biothera; IGF Oncology; Vanquish Oncology
Honoraria - EMD Serono; IGF Oncology; Martell diagnostic; Squarex Pharma; TTC Oncology; Vanquish Oncology
Consulting or Advisory Role - TTC Oncology; Tychon
Research Funding - Lilly (Inst); Merck (Inst)
 
Hossein Borghaei
Honoraria - Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; EMD Serono; Genentech; Genmab; HUYA Bioscience International; Lilly; Merck; Novartis; Pfizer; PharmaMar; Regeneron; Rgenix; Sonnet; Takeda; Trovagene
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis
Other Relationship - Incyte; Takeda; University of Pennsylvania
 
Julie R. Brahmer
Honoraria - Roche/Genentech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genentech; Janssen Oncology; Lilly; Merck; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Revolution; Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Janssen Oncology; merck
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Loxo; Merck; Nektar; Takeda; Tesaro
Research Funding - Abbvie (Inst); Advaxis (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genmab (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - AstraZeneca